Sequence-dependent Synergistic Effect of Aumolertinib-pemetrexed Combined Therapy on EGFR-mutant Non-small-cell Lung Carcinoma with Pre-clinical and Clinical Evidence

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2022 May 3

PMID 35501907

Authors

Luyao Ao

Shencun Fang

Kexin Zhang

Yang Gao

Jiawen Cui

Wenjing Jia

Yunlong Shan

Jingwei Zhang

Guangji Wang

Jiali Liu

Fang Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Inevitably developed resistance of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) limited its clinical benefit on non-small cell lung cancer (NSCLC). Upfront combination therapy is promising to prevent this resistance. Compelling clinical evidence indicated the failure of third-generation EGFR TKIs combined with either immunotherapy or antiangiogenic agents. In comparison, combined treatment of third-generation EGFR TKIs and chemotherapy might be a favorable choice. Herein, we systematically analyzed and compared the effects of pemetrexed and a novel third-generation EGFR TKI aumolertinib combined in different sequences, subsequently revealed the potential mechanisms and proved the optimal combination schedule with clinical retrospective study.

Methods: Three combination schedules involving pemetrexed and aumolertinib in different sequences were developed. Their inhibition effects on cell proliferation and metastasis were firstly compared upon three human NSCLC cell lines in vitro, by cell counting kit-8, colony formation, wound healing and transwell assays respectively. Further evaluation in vivo was proceeded upon H1975 and HCC827 xenograft model. Gene and protein expression were detected by Q-PCR and western blot. Drug concentration was determined by LC-MS/MS. VEGF secretion was determined by ELISA. Tumor vessel was visualized by immunofluorescence. Lastly, a clinical retrospective study was raised with 65 patients' data.

Results: The combination of pemetrexed and aumolertinib exhibited a sequence-dependent and EGFR mutant-dependent synergistic effect in vitro and in vivo. Only treatment with aumolertinib following pemetrexed (P-A) exhibited synergistic effect with stronger anti-tumor growth and anti-metastasis ability than monotherapy and also other combination sequences. This synergism could exclusively be observed in H1975 and HCC827 but not A549. Pathway analysis showed that P-A significantly enhanced the suppression of EGFR pathway. In addition, our results intriguingly found an obvious reduction of VEGF secretion and the accompanying normalization of the intratumor vessel, consequently increasing intratumoral accumulation of pemetrexed in P-A group. Finally, the clinical retrospective study verified the synergistic effect of P-A combination by significantly superior tumor response than aumolertinib monotherapy.

Conclusion: Aumolertinib-pemetrexed combined therapy is promising for EGFR mutant NSCLC but only in right administration sequence. P-A could become an advantageous combination strategy in clinical with synergistic inhibition of tumor growth and metastasis.

Citing Articles

The influence of drug-induced metabolic enzyme activity inhibition and CYP3A4 gene polymorphism on aumolertinib metabolism.

Ye F, Ni J, Li X, Wang J, Luo J, Wang S Front Pharmacol. 2024; 15:1392849.

PMID: 38855755 PMC: 11157048. DOI: 10.3389/fphar.2024.1392849.

Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review.

Zhang Q, Wang R, Xu L Transl Cancer Res. 2024; 12(12):3764-3778.

PMID: 38192990 PMC: 10774042. DOI: 10.21037/tcr-23-956.

Aumolertinib: effective treatment for asymptomatic pulmonary giant cell carcinoma with L858R mutation - a case report.

Yang W, Yang Z, Wang K, Zhu P, Pu J Front Oncol. 2023; 13:1279045.

PMID: 38090500 PMC: 10711212. DOI: 10.3389/fonc.2023.1279045.

Methyl eugenol protects the kidney from oxidative damage in mice by blocking the Nrf2 nuclear export signal through activation of the AMPK/GSK3β axis.

Kuang B, Wang Z, Hou S, Zhang J, Wang M, Zhang J Acta Pharmacol Sin. 2022; 44(2):367-380.

PMID: 35794373 PMC: 9889399. DOI: 10.1038/s41401-022-00942-2.

References

Westover D, Zugazagoitia J, Cho B, Lovly C, Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29(suppl_1):i10-i19. PMC: 6454547. DOI: 10.1093/annonc/mdx703. View

Liu T, Jin L, Lu W, Gan H, Lin Z, Chen M . Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo. J Exp Clin Cancer Res. 2019; 38(1):148. PMC: 6451286. DOI: 10.1186/s13046-019-1133-z. View

Zhou L, Hu Y, Li C, Yan Y, Ao L, Yu B . Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway. Neuropharmacology. 2018; 135:34-47. DOI: 10.1016/j.neuropharm.2018.03.004. View

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

Oxnard G, Yang J, Yu H, Kim S, Saka H, Horn L . TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020; 31(4):507-516. DOI: 10.1016/j.annonc.2020.01.013. View

La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M . Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Exp Clin Cancer Res. 2019; 38(1):222. PMC: 6537372. DOI: 10.1186/s13046-019-1240-x. View

Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A . TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(25):5892-9. DOI: 10.1200/JCO.2005.02.840. View

Herbst R, Giaccone G, Schiller J, Natale R, Miller V, Manegold C . Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004; 22(5):785-94. DOI: 10.1200/JCO.2004.07.215. View

10.

Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N . Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2.... JAMA Oncol. 2021; 7(3):386-394. PMC: 7791398. DOI: 10.1001/jamaoncol.2020.6758. View

11.

Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-Finn C . Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv192-iv237. DOI: 10.1093/annonc/mdy275. View

12.

Hata A, Niederst M, Archibald H, Gomez-Caraballo M, Siddiqui F, Mulvey H . Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016; 22(3):262-9. PMC: 4900892. DOI: 10.1038/nm.4040. View

13.

Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A . Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2019; 38(2):115-123. DOI: 10.1200/JCO.19.01488. View

14.

Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V . Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer. 2014; 13:230. PMC: 4198757. DOI: 10.1186/1476-4598-13-230. View

15.

Han B, Jin B, Chu T, Niu Y, Dong Y, Xu J . Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. Int J Cancer. 2017; 141(6):1249-1256. DOI: 10.1002/ijc.30806. View

16.

Park J, Kim I, Han S, Park I, Kim C, Bae J . Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. Cancer Cell. 2016; 30(6):953-967. DOI: 10.1016/j.ccell.2016.10.018. View

17.

Nilsson M, Robichaux J, Herynk M, Cascone T, Le X, Elamin Y . Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol. 2020; 16(3):439-451. PMC: 8207565. DOI: 10.1016/j.jtho.2020.11.022. View

18.

Kumagai S, Koyama S, Nishikawa H . Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021; 21(3):181-197. DOI: 10.1038/s41568-020-00322-0. View

19.

Carmeliet P, Jain R . Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011; 10(6):417-27. DOI: 10.1038/nrd3455. View

20.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F . Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Lung Cancer. 2018; 124:65-70. DOI: 10.1016/j.lungcan.2018.07.031. View